Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (vol 24, pg 1649, 2018)

被引：11

作者：

Amaria, Rodabe N.

Reddy, Sangeetha M.

Tawbi, Hussein A.

Davies, Michael A.

Ross, Merrick I.

Glitza, Isabella C.

Cormier, Janice N.

Lewis, Carol

Hwu, Wen-Jen

Hanna, Ehab

Diab, Adi

Wong, Michael K.

Royal, Richard

Gross, Neil

Weber, Randal

Lai, Stephen Y.

Ehlers, Richard

Blando, Jorge

Milton, Denai R.

Woodman, Scott

Kageyama, Robin

Wells, Daniel K.

Hwu, Patrick

Patel, Sapna P.

Lucci, Anthony

Hessel, Amy

Lee, Jeffrey E.

Gershenwald, Jeffrey

Simpson, Lauren

Burton, Elizabeth M.

Posada, Liberty

Haydu, Lauren

Wang, Linghua

Zhang, Shaojun

Lazar, Alexander J.

Hudgens, Courtney W.

Gopalakrishnan, Vancheswaran

Reuben, Alexandre

Andrews, Miles C.

Spencer, Christine N.

Prieto, Victor

Sharma, Padmanee

Allison, James

Tetzlaff, Michael T.

Wargo, Jennifer A.

机构：

[1] MD Anderson Cancer Center,Department of Melanoma Medical Oncology

[2] MD Anderson Cancer Center,Department of Breast Medical Oncology

[3] MD Anderson Cancer Center,Department of Surgical Oncology

[4] MD Anderson Cancer Center,Department of Head and Neck Surgery

[5] MD Anderson Cancer Center,Department of Immunology

[6] MD Anderson Cancer Center,Department of Biostatistics

[7] Parker Institute for Cancer Immunotherapy,Department of Genomic Medicine

[8] MD Anderson Cancer Center,Department of Pathology

[9] MD Anderson Cancer Center,Department of Genitourinary Cancers

[10] MD Anderson Cancer Center,Department of Translational and Molecular Pathology

[11] MD Anderson Cancer Center,undefined

来源：

NATURE MEDICINE | 2018年 / 24卷 / 12期

关键词：

D O I：

10.1038/s41591-018-0252-y

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In the version of this article originally published, there was an error in Fig. 1. In the neoadjuvant phase column, the n values for arms A and B were both reported to be 20. The n values for arms A and B were actually 12 and 11, respectively. Also, the URL underlying the accession code in the data availability section was incorrect. The URL was originally https://www.ebi.ac.uk/ega/studies/EGAS00001002698. It should have been https://www.ebi.ac.uk/ega/studies/EGAS00001003178. The errors have been corrected in the print, HTML and PDF versions of this article.

引用

页码：1942 / 1942

页数：1

共 50 条

[21] Optimal systemic therapy for high-risk resectable melanoma
Alexander M. M. Eggermont
Omid Hamid
Georgia V. Long
Jason J. Luke
Nature Reviews Clinical Oncology, 2022, 19 : 431 - 439
[22] Neoadjuvant relatlimab and nivolumab in resectable melanoma (vol 611, pg 155, 2022)
Amaria, Rodabe N.
Postow, Michael
Burton, Elizabeth M.
Tetzlaff, Michael T.
Ross, Merrick I.
Torres-Cabala, Carlos
Glitza, Isabella C.
Duan, Fei
Milton, Denai R.
Busam, Klaus
Simpson, Lauren
McQuade, Jennifer L.
Wong, Michael K.
Gershenwald, Jeffrey E.
Lee, Jeffrey E.
Goepfert, Ryan P.
Keung, Emily Z.
Fisher, Sarah B.
Betof-Warner, Allison
Shoushtari, Alexander N.
Callahan, Margaret
Coit, Daniel
Bartlett, Edmund K.
Bello, Danielle
Momtaz, Parisa
Nicholas, Courtney
Gu, Aidi
Zhang, Xuejun
Korivi, Brinda Rao
Patnana, Madhavi
Patel, Sapna P.
Diab, Adi
Lucci, Anthony
Prieto, Victor G.
Davies, Michael A.
Allison, James P.
Sharma, Padmanee
Wargo, Jennifer A.
Ariyan, Charlotte
Tawbi, Hussein A.
NATURE, 2023, 615 (7953) : E23 - E23
[23] Neoadjuvant Dual Checkpo intInhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis(vol 10, pg 612, 2024)
Mangla, A.
Lee, C.
Mirsky, M. M.
JAMA ONCOLOGY, 2024, 10 (08) : 1138 - 1138
[24] Older age predicts better outcome to neoadjuvant immune checkpoint blockade in metastatic melanoma
Thakur, Rohit
Douglass, Stephen
Helmink, Beth
Amaria, Rodabe
Tawbi, Hussein
McQuade, Jennifer
Rozeman, Eliza
Burton, Elizabeth
Reddy, Sangeetha
Wherry, John
Blank, Christian
Long, Georgina
Gershenwald, Jeffrey
Davies, Michael
Tetzlaff, Michael
Weeraratna, Ashani
Wargo, Jennifer
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[25] Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
Itske Fraterman
Irene L. M. Reijers
Petros Dimitriadis
Annegien Broeks
M. Gonzalez
A. M. M. Menzies
Marta Lopez-Yurda
Ellen Kapiteijn
Astrid A. M. van der Veldt
Karijn P. M. Suijkerbuijk
Geke A. P. Hospers
Georgina V. Long
Christian U. Blank
Lonneke V. van de Poll-Franse
Nature Medicine, 2023, 29 : 3090 - 3099
[26] Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma
Song, Yun
Straker, Richard J., III
Xu, Xiaowei
Elder, David E.
Gimotty, Phyllis A.
Huang, Alexander C.
Mitchell, Tara C.
Amaravadi, Ravi K.
Schuchter, Lynn M.
Karakousis, Giorgos C.
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (08) : 2915 - 2926
[27] Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
Fraterman, Itske
Reijers, Irene L. M.
Dimitriadis, Petros
Broeks, Annegien
Gonzalez, M.
Menzies, A. M. M.
Lopez-Yurda, Marta
Kapiteijn, Ellen
van der Veldt, Astrid A. M.
Suijkerbuijk, Karijn P. M.
Hospers, Geke A. P.
Long, Georgina V.
Blank, Christian U.
van de Poll-franse, Lonneke V.
NATURE MEDICINE, 2023, 29 (12) : 3090 - 3099
[28] Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma
Yun Song
Richard J. Straker
Xiaowei Xu
David E. Elder
Phyllis A. Gimotty
Alexander C. Huang
Tara C. Mitchell
Ravi K. Amaravadi
Lynn M. Schuchter
Giorgos C. Karakousis
Annals of Surgical Oncology, 2020, 27 : 2915 - 2926
[29] Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies (vol 33, pg 581, 2018)
Zappasodi, Roberta
Merghoub, Taha
Wolchok, Jedd D.
CANCER CELL, 2018, 34 (04) : 690 - 690
[30] Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma
Rohila, Deepak
Park, In Hwan
Pham, Timothy V. V.
Jones, Riley
Tapia, Elisabette
Liu, Kevin X. X.
Tamayo, Pablo
Yu, Alice
Sharabi, Andrew B. B.
Joshi, Shweta
FRONTIERS IN IMMUNOLOGY, 2023, 14

← 1 2 3 4 5 →